277 related articles for article (PubMed ID: 30238781)
1. Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries.
Eder S; Leierer J; Kerschbaum J; Rosivall L; Wiecek A; de Zeeuw D; Mark PB; Heinze G; Rossing P; Heerspink HL; Mayer G
Diab Vasc Dis Res; 2019 Jan; 16(1):47-56. PubMed ID: 30238781
[TBL] [Abstract][Full Text] [Related]
2. Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases.
Bramlage P; Lanzinger S; van Mark G; Hess E; Fahrner S; Heyer CHJ; Friebe M; Seufert J; Danne T; Holl RW
Cardiovasc Diabetol; 2019 Mar; 18(1):33. PubMed ID: 30878037
[TBL] [Abstract][Full Text] [Related]
3. Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease.
Kobayashi K; Toyoda M; Kaneyama N; Hatori N; Furuki T; Sakai H; Takihata M; Umezono T; Ito S; Suzuki D; Takeda H; Kanamori A; Degawa H; Yamamoto H; Machimura H; Mokubo A; Chin K; Obana M; Hishiki T; Aoyama K; Nakajima S; Umezawa S; Shimura H; Aoyama T; Miyakawa M
J Diabetes Res; 2019; 2019():9415313. PubMed ID: 31781668
[TBL] [Abstract][Full Text] [Related]
4. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
[TBL] [Abstract][Full Text] [Related]
5. Assessing variability in compliance with recommendations given by the International Diabetes Federation (IDF) for patients with type 2 diabetes in primary care using electronic records. The APNA study.
Brugos-Larumbe A; Aldaz-Herce P; Guillen-Grima F; Garjón-Parra FJ; Bartolomé-Resano FJ; Arizaleta-Beloqui MT; Pérez-Ciordia I; Fernández-Navascués AM; Lerena-Rivas MJ; Berjón-Reyero J; Jusué-Rípodas L; Aguinaga-Ontoso I
Prim Care Diabetes; 2018 Feb; 12(1):34-44. PubMed ID: 28732655
[TBL] [Abstract][Full Text] [Related]
6. Regional differences in insulin therapy regimens in five European countries
.
Rathmann W; Czech M; Franek E; Kostev K
Int J Clin Pharmacol Ther; 2017 May; 55(5):403-408. PubMed ID: 28257286
[TBL] [Abstract][Full Text] [Related]
7. A Population-Based Analysis of Quality Indicators in CKD.
Manns L; Scott-Douglas N; Tonelli M; Weaver R; Tam-Tham H; Chong C; Hemmelgarn B
Clin J Am Soc Nephrol; 2017 May; 12(5):727-733. PubMed ID: 28377473
[TBL] [Abstract][Full Text] [Related]
8. Changes in the management of type 2 diabetic patients in family medicine practices in the Bursa region.
Göktaş O; Öz Gül Ö; Ertürk E
Prim Care Diabetes; 2017 Apr; 11(2):178-183. PubMed ID: 27852516
[TBL] [Abstract][Full Text] [Related]
9. A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) - Study Design and Baseline Characteristics.
Eder S; Leierer J; Kerschbaum J; Rosivall L; Wiecek A; de Zeeuw D; Mark PB; Heinze G; Rossing P; Heerspink HL; Mayer G
Kidney Blood Press Res; 2018; 43(1):181-190. PubMed ID: 29466797
[TBL] [Abstract][Full Text] [Related]
10. Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries.
Hermans MP; Brotons C; Elisaf M; Michel G; Muls E; Nobels F;
Eur J Prev Cardiol; 2013 Dec; 20(6):1095-105. PubMed ID: 22605788
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of chronic kidney disease in Finnish patients with type 2 diabetes treated in primary care.
Metsärinne K; Bröijersen A; Kantola I; Niskanen L; Rissanen A; Appelroth T; Pöntynen N; Poussa T; Koivisto V; Virkamäki A;
Prim Care Diabetes; 2015 Feb; 9(1):31-8. PubMed ID: 25066820
[TBL] [Abstract][Full Text] [Related]
12. Patterns and trends in insulin intensification among patients with type 2 diabetes: a systematic review.
Polinski JM; Connolly JG; Curtis BH; Seeger JD; Gaskins K; Perez M; Smith BF; Shrank WH
Prim Care Diabetes; 2014 Jul; 8(2):101-9. PubMed ID: 24275103
[TBL] [Abstract][Full Text] [Related]
13. PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.
Fici F; Ari Bakir E; Ilkay Yüce E; Kanuncu S; Makel W; Tarim BA; Robles NR
High Blood Press Cardiovasc Prev; 2020 Feb; 27(1):43-49. PubMed ID: 31916208
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
Kobayashi K; Toyoda M; Kimura M; Hatori N; Furuki T; Sakai H; Takihata M; Umezono T; Ito S; Suzuki D; Takeda H; Kanamori A; Degawa H; Yamamoto H; Machimura H; Mokubo A; Chin K; Obana M; Hishiki T; Aoyama K; Nakajima S; Umezawa S; Shimura H; Aoyama T; Sato K; Miyakawa M
Diab Vasc Dis Res; 2019 Jan; 16(1):103-107. PubMed ID: 30284913
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of anemia in patients with type II diabetes and mild to moderate chronic kidney disease and the impact of anti-RAS medications.
Dousdampanis P; Trigka K; Fourtounas C
Saudi J Kidney Dis Transpl; 2014 May; 25(3):552-7. PubMed ID: 24821151
[TBL] [Abstract][Full Text] [Related]
16. Annual deterioration of renal function in hypertensive patients with and without diabetes.
Polonia J; Azevedo A; Monte M; Silva JA; Bertoquini S
Vasc Health Risk Manag; 2017; 13():231-237. PubMed ID: 28721063
[TBL] [Abstract][Full Text] [Related]
17. Quality of care in patients with diabetic kidney disease in Asia: The Joint Asia Diabetes Evaluation (JADE) Registry.
Luk AO; Li X; Zhang Y; Guo X; Jia W; Li W; Weng J; Yang W; Chan WB; Ozaki R; Tsang CC; Mukhopadhyay M; Ojha AK; Hong EG; Yoon KH; Sobrepena L; Toledo RM; Duran M; Sheu W; Q Do T; Nguyen TK; Ma RC; Kong AP; Chow CC; Tong PC; So WY; Chan JC;
Diabet Med; 2016 Sep; 33(9):1230-9. PubMed ID: 26511783
[TBL] [Abstract][Full Text] [Related]
18. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).
Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K
Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298
[TBL] [Abstract][Full Text] [Related]
19. Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus.
Nargesi AA; Jeyashanmugaraja GP; Desai N; Lipska K; Krumholz H; Khera R
J Am Heart Assoc; 2021 Jul; 10(13):e021084. PubMed ID: 33998258
[TBL] [Abstract][Full Text] [Related]
20. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study.
Penfornis A; Blicklé JF; Fiquet B; Quéré S; Dejager S
Vasc Health Risk Manag; 2014; 10():341-52. PubMed ID: 24966684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
